All News

Physicians contemplating retirement within a few years need to understand the future risks of the financial situation they may be facing.

Physicians spend an enormous amount of time processing, creating, and storing electronic information. These tasks can seem overwhelming at times, but there are ways to streamline them.

Older men with at least two lower urinary tract symptoms are more likely to have recently thought about committing suicide, researchers say.

Running ancillary service lines increases care accessibility and allows providers to know the quality of the care being given, say urologists.

With a deluge of new drug treatments for advanced prostate cancer on the market, a care model emphasizing urologist and medical oncologist collaboration is needed, according to an article whose authors represent each specialty.

The FDA has granted 510(k) clearance for American Medical Systems, Inc.’s RetroArc retropubic sling system for treatment of female stress urinary incontinence.

Out-of-pocket costs for couples being treated for infertility range from a low of $912 for medication only to $19,234 for in vitro fertilization, according to researchers who say their data will help couples plan for the expenses they may incur.

Risk classification changed in more than half of prostate cancers following assessment of cell cycle progression in tumors, according to a study reported at the Society of Urologic Oncology meeting in Bethesda, MD.

In this article, we briefly review the evaluation of patients with PPI and discuss the benefits and drawbacks of conservative, pharmacologic, injection, and surgical treatments.

Congress may be ready to trade in the SGR for a VBP and an APM to fix the difficult physician fee schedule situation that has plagued urologists and other Medicare physicians for a decade. But while the AUA wants the SGR to go away, the organization has significant reservations about this latest plan.

The presence of a particular protein in biopsied prostate tissue substantially increases the likelihood that cancer will develop there, according to recent study.

The FDA has approved collagenase clostridium histolyticum (CCH [XIAFLEX]) as the first medication to treat of Peyronie's disease (PD).

The AUA recently joined with the American Association of Clinical Urologists and the Large Urology Group Practice Association in applauding the Physician’s Caucus of the United States Senate for their “commitment to preserving patient access to independent, integrated medical services.”

Men with hormone-sensitive metastatic prostate cancer who received docetaxel (Taxotere) given at the start of standard hormone therapy lived longer than patients who received hormone therapy alone, according to early study results that the lead investigator called “practice changing.”

Declining reimbursement remains the number one concern of practicing urologists, according to findings from the 8th installment of Urology Times' exclusive State of the Specialty survey.

British scientists have discovered that the presence of a specific protein can distinguish between indolent and aggressive prostate cancer.

When the pros and cons of prostate cancer treatment are spelled out using an online interactive program, more patients choose active surveillance over definitive treatment, according to researchers from Thomas Jefferson University in Philadelphia who developed the program.

Ceftolozane/tazobactam, an investigational antibiotic, showed positive top-line results in a pivotal phase III clinical trial of the drug’s use in complicated urinary tract infections, Cubist Pharmaceuticals, Inc. reported.

Data from phase III studies of collagenase clostridium histolyticum (CCH [XIAFLEX]) showed that the agent met primary endpoints related to Peyronie’s disease (PD) curvature and symptoms, and that it is effective and safe in certain subgroups of men with PD, according to Auxilium Pharmaceuticals, Inc.

The latest products and services from Mission Pharmacal, Eli Lilly, Richard Wolf Medical Instruments Corp., and Inspire on Purpose Publishing.

Men with prostate cancer who ate a low-fat diet and took fish oil supplements had lower levels of pro-inflammatory substances in their blood and a lower cell cycle progression score than men who ate a typical Western diet, UCLA researchers reported.

An investigational prostate cancer treatment slows the disease’s progression and may increase survival, especially among men whose cancer has metastasized to the bones, according to a recent analysis.

Older men with midrange testosterone levels tend to live longer compared with men who have low or high levels, Australian researchers say.

GenomeDx Biosciences has entered into contractual agreements for diagnostic laboratory testing as a participating provider that will expand insurance coverage for the company’s Decipher test for prostate cancer.

Contrary to popular belief and scientific predictions, a man’s patency after vasectomy reversal is possible almost 40 years after the original vasectomy, according to a study of more than 1,200 reversals that the authors say is the largest such study ever published.

Men with prostate cancer treated with androgen deprivation therapy had significant improvement in strength and exercise capacity following a 10-week program of physical activity, education, and support, according to a study reported at the AUA annual meeting in San Diego.

A new staging system for anterior urethral strictures is easy to use, demonstrates good reliability, and is expected to have useful applications in research and clinical care, say researchers from Cornell University’s Weill Medical College, New York.

Astellas Pharma US, Inc. and Medivation, Inc. have initiated a phase IV trial to evaluate the benefit of continued treatment with enzalutamide (Xtandi) beyond disease progression in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer.

Juan Reyna, MD, is the new president of the Large Urology Group Practice Association.

As the year comes to an end, federal lawmakers still have much to address with Obamacare’s problematic launch and time running out to pass a repeal of the fundamentally flawed Medicare sustainable growth rate by the end of the year.